What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

What changed

123 changes recorded since monitoring began on 2026-08-21, of 5 different kinds. This is the page that cannot be reconstructed anywhere else: ClinicalTrials.gov and the FDA shortage database both overwrite a record when it changes, keeping no public history of what it used to say. A completion date moving out by two years, a phase 3 trial quietly changing status, a presentation flipping to discontinued — each is invisible the day after it happens unless something was watching. Each row below carries the previous value alongside the new one.

Six times a day we snapshot the registry and compare it to the previous one. When a company quietly pushes a reporting date back, halts a trial or resizes an enrollment, ClinicalTrials.gov shows the new value and says nothing about the old one. So we keep the old one. Changes marked lead are phase 3 movements of six months or more, or phase 3 halts.

123
changes on record
10
lead-story changes
103
trials affected
10
days observed
DetectedChangeDrugTrialDetailPhase
2026-09-03New trial registeredtirzepatide
· ELI LILLY AND CO
2026-09-03New trial registeredtirzepatide
· ELI LILLY AND CO
2026-09-03field_changedtirzepatide
·
2026-09-03field_changedtirzepatide
·
2026-09-03field_changedtirzepatide
·
2026-09-03field_changedtirzepatide
·
2026-09-03Enrollment changedsemaglutideBariatric Surgery vs. Semaglutide vs. Tirzepatide
NCT06803888 · Ali Aminian
125 → 140 participantsP4
2026-09-03New trial registeredsemaglutidePhase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
NCT07801820 · Shanghai Minwei Biotechnology Co., Ltd
Recruiting, n=240P2
2026-09-02Results date movedsemaglutideEfficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT06762314 · Mostafa Bahaa
2027-09-202026-01-20 20 mo earlierP2
2026-09-02Status changedsemaglutideEfficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT06762314 · Mostafa Bahaa
Recruiting → CompletedP2
2026-09-02Enrollment changedsemaglutideEfficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT06762314 · Mostafa Bahaa
105 → 114 participantsP2
2026-09-02Status changedsemaglutideEffect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction
NCT06557811 · University of Sao Paulo General Hospital
Not yet recruiting → UnknownP4
2026-09-01New trial registeredsemaglutidePostpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes
NCT07797036 · University of Massachusetts, Worcester
Not yet recruiting, n=226P2/P3
2026-09-01Results date movedsemaglutideA Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
NCT06299098 · Regeneron Pharmaceuticals
2026-05-062026-06-16 1 mo laterP2
2026-09-01New trial registeredtirzepatideA Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
NCT07796477 · CSPC Ouyi Pharmaceutical Co., Ltd.
Not yet recruiting, n=240P2
2026-08-31New trial registeredorforglipronA Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579 · Eli Lilly and Company
Not yet recruiting, n=2,001P3
2026-08-31New trial registeredpemvidutidePhase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
NCT07795164 · Altimmune, Inc.
Recruiting, n=1,800P3
2026-08-31Status changedsemaglutideEarly Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth: A Randomized Clinical Trial
NCT06934655 · Children's Hospital Los Angeles
Not yet recruiting → RecruitingP3
2026-08-31Status changedliraglutideA Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
NCT06559722 · Tonghua Dongbao Pharmaceutical Co.,Ltd
Not yet recruiting → UnknownP3
2026-08-31Status changedmazdutideA Study of IBI362 9 mg in Chinese Adults With Obesity
NCT06164873 · Innovent Biologics (Suzhou) Co. Ltd.
Active, not recruiting → UnknownP3
2026-08-31Status changedecnoglutideA Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
NCT07734311 · Hangzhou Sciwind Biosciences Co., Ltd.
Not yet recruiting → RecruitingP3
2026-08-28field_changed leadliraglutide
·
2026-08-28Status changed leadliraglutide
·
Current → To Be Discontinued
2026-08-28field_changed leadliraglutide
·
2026-08-28Status changedliraglutide
·
To Be Discontinued → Current
2026-08-28field_changedliraglutide
·
2026-08-28Results date movedsemaglutideGLP-1R Agonist Treatment for Opioid Use Disorder
NCT06548490 · Milton S. Hershey Medical Center
2027-042027-04-30P2
2026-08-28Status changedtirzepatideTirzepatide in Idiopathic Intracranial Hypertension Trial
NCT07191873 · Duke University
Not yet recruiting → RecruitingP4
2026-08-28Results date movedmazdutideEffect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
NCT07657676 · China National Center for Cardiovascular Diseases
2027-10-312027-12-31 2 mo laterP4
2026-08-27New trial registered leadtirzepatide
· ELI LILLY AND CO
2026-08-27New trial registered leadtirzepatide
· ELI LILLY AND CO
2026-08-27New trial registeredsemaglutide
· NOVO
2026-08-27Status changedtirzepatideGLP-1R Actions on Muscle and the Skeleton
NCT07154719 · Pennington Biomedical Research Center
Active, not recruiting → RecruitingP4
2026-08-27New trial registeredorforglipronA Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861 · Eli Lilly and Company
Not yet recruiting, n=192P3
2026-08-26New trial registered leadtirzepatide
· ELI LILLY AND CO
2026-08-26Results date movedtirzepatideA Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
NCT07349641 · National Cancer Institute (NCI)
2028-12-312029-10-31 10 mo laterP2
2026-08-25Status changed leadliraglutide
·
Current → To Be Discontinued
2026-08-25field_changed leadliraglutide
·
2026-08-25field_changed leadliraglutide
·
2026-08-25field_changed leadliraglutide
·
2026-08-25New trial registeredsemaglutideA Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity
NCT07783854 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not yet recruiting, n=72P4
2026-08-24Status changedtirzepatideIncretin Therapies in Obesity-related HFpEF
NCT07554638 · Columbia University
Not yet recruiting → RecruitingP4
2026-08-24New trial registeredmazdutideMazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
NCT07781150 · Tongji Hospital
Not yet recruiting, n=128P2
2026-08-24Status changedmaridebart cafraglutideExtension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144 · Amgen
Not yet recruiting → RecruitingP3
2026-08-21New trial registeredlixisenatideiGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
NCT05413369 · Sanofi
Completed, n=582P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
NCT02058160 · Sanofi
Completed, n=736P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
NCT02058147 · Sanofi
Completed, n=1,170P3
2026-08-21New trial registeredlixisenatideEvaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
NCT01147250 · Sanofi
Completed, n=6,068P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
NCT02752412 · Sanofi
Completed, n=513P3
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
NCT00712673 · Sanofi
Completed, n=680P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
NCT01768559 · Sanofi
Completed, n=894P3
2026-08-21New trial registeredlixisenatideEvaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
NCT03798054 · Sanofi
Completed, n=878P3
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
NCT00713830 · Sanofi
Completed, n=859P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
NCT02752828 · Sanofi
Completed, n=521P3
2026-08-21New trial registeredaleniglipronA Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Recruiting, n=1,100P3
2026-08-21New trial registeredaleniglipronEfficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Recruiting, n=3,600P3
2026-08-21New trial registeredalbiglutideA Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
NCT00839527 · GlaxoSmithKline
Completed, n=685P3
2026-08-21New trial registeredalbiglutideA Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
NCT00976391 · GlaxoSmithKline
Completed, n=586P3
2026-08-21New trial registeredalbiglutideA Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
NCT01098539 · GlaxoSmithKline
Completed, n=507P3
2026-08-21New trial registeredalbiglutideA Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
NCT00838916 · GlaxoSmithKline
Completed, n=779P3
2026-08-21New trial registeredalbiglutideSafety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
NCT02229227 · GlaxoSmithKline
Completed, n=814P3
2026-08-21New trial registeredalbiglutideEfficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
NCT00838903 · GlaxoSmithKline
Completed, n=1,049P3
2026-08-21New trial registeredlixisenatideLixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes
NCT02049034 · University of Surrey
Completed, n=8P4
2026-08-21New trial registeredlixisenatideRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
NCT07173712 · Yanbing Li
Not yet recruiting, n=324P4
2026-08-21New trial registeredlixisenatideSafety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
NCT01940965 · Sanofi
Completed, n=294P3
2026-08-21New trial registeredlixisenatideComparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
NCT03798080 · Sanofi
Completed, n=426P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
NCT01798706 · Sanofi
Completed, n=350P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
NCT02749890 · Sanofi
Completed, n=321P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
NCT03434119 · Sanofi
Terminated, n=241P3
2026-08-21New trial registeredlixisenatideEvaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
NCT07117240 · Medical University of Warsaw
Enrolling by invitation, n=100P4
2026-08-21New trial registeredlixisenatideImpact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
NCT01910194 · Profil Institut für Stoffwechselforschung GmbH
Completed, n=39P2
2026-08-21New trial registeredlixisenatideStudy Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
NCT03767543 · Sanofi
Completed, n=265P3
2026-08-21New trial registeredlixisenatideThe Effect of Lixisenatide on the Effect of Pituitary Hormones
NCT05804513 · University of Tartu
Unknown, n=10P4
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
NCT00715624 · Sanofi
Completed, n=496P3
2026-08-21New trial registeredlixisenatideStudy to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
NCT03439943 · University Hospital, Toulouse
Completed, n=156P2
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
NCT00905255 · Sanofi
Completed, n=69P3
2026-08-21New trial registeredlixisenatideThe Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
NCT03819790 · LMC Diabetes & Endocrinology Ltd.
Completed, n=119P4
2026-08-21New trial registeredlixisenatideEvaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
NCT02767596 · Laniado Hospital
Terminated, n=2P4
2026-08-21New trial registeredlixisenatideSafety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
NCT01960179 · Sanofi
Completed, n=361P3
2026-08-21New trial registeredlixisenatideSafety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
NCT02941367 · Sanofi
Completed, n=184P4
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
NCT00763815 · Sanofi
Completed, n=484P3
2026-08-21New trial registeredlixisenatideStudy on Lixisenatide and Counterregulation to Hypoglycemia
NCT02020629 · Lund University
Completed, n=18P4
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
NCT00688701 · Sanofi
Completed, n=361P3
2026-08-21New trial registeredlixisenatideEffects of Insulin Glargine and Lixisenatide on the Brain
NCT03881995 · University Hospital Tuebingen
Terminated, n=1P4
2026-08-21New trial registeredlixisenatideEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
NCT03529123 · Sanofi
Completed, n=247P3
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
NCT01169779 · Sanofi
Completed, n=391P3
2026-08-21New trial registeredlixisenatide24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
NCT00976937 · Sanofi
Completed, n=319P3
2026-08-21New trial registeredlixisenatide24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
NCT00975286 · Sanofi
Completed, n=446P3
2026-08-21New trial registeredlixisenatideEffect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
NCT05114590 · Sanofi
Completed, n=124P4
2026-08-21New trial registeredlixisenatideiGlarLixi CGM Study in Chinese T2D Individuals After OADs
NCT06671587 · Sanofi
Recruiting, n=678P4
2026-08-21New trial registeredlixisenatideDose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
NCT00299871 · Sanofi
Completed, n=542P2
2026-08-21New trial registeredlixisenatideEfficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
NCT01476475 · Sanofi
Completed, n=323P2
2026-08-21New trial registeredlixisenatideEfficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235 · Shanghai Zhongshan Hospital
Recruiting, n=1,316P4
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
NCT00866658 · Sanofi
Completed, n=311P3
2026-08-21New trial registeredlixisenatideFeasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
NCT02168491 · Medical University of Vienna
Completed, n=10P3
2026-08-21New trial registeredlixisenatideEffect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
NCT02274740 · Sanofi
Terminated, n=2P2
2026-08-21New trial registeredlixisenatideGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
NCT00763451 · Sanofi
Completed, n=484P3
2026-08-21New trial registeredlixisenatideEffect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
NCT02200991 · Sanofi
Completed, n=136P4
2026-08-21New trial registeredlixisenatideRemission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
NCT03130426 · Population Health Research Institute
Completed, n=161P3
2026-08-21New trial registeredlixisenatideA Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
NCT06716424 · Sanofi
Completed, n=105P4
2026-08-21New trial registeredlixisenatideEffect of LIXIsenatide on the Renal System
NCT02276196 · Amsterdam UMC, location VUmc
Completed, n=40P4
2026-08-21New trial registeredlixisenatideAssessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
NCT01632163 · Sanofi
Completed, n=447P3
2026-08-21New trial registeredlixisenatideComparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
NCT01517412 · Sanofi
Completed, n=451P3
2026-08-21New trial registeredaleniglipronAleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Active, not recruiting, n=58P2
2026-08-21New trial registeredaleniglipronAleniglipron Phase 2 Body Composition Study
NCT07169942 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Active, not recruiting, n=71P2
2026-08-21New trial registeredaleniglipronA Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06693843 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Completed, n=230P2
2026-08-21New trial registeredaleniglipronA Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06703021 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Completed, n=85P2
2026-08-21New trial registeredolatorepatideStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
NCT07685808 · Regeneron Pharmaceuticals
Recruiting, n=360P2
2026-08-21New trial registeredolatorepatideStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086 · Regeneron Pharmaceuticals
Active, not recruiting, n=120P2
2026-08-21New trial registeredalbiglutideAlbiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
NCT02284009 · GlaxoSmithKline
Completed, n=67P2
2026-08-21New trial registeredalbiglutideDose Ranging Study of Albiglutide in Japanese Subjects
NCT01098461 · GlaxoSmithKline
Completed, n=215P2
2026-08-21New trial registeredalbiglutideA Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus
NCT03015519 · GlaxoSmithKline
WithdrawnP3
2026-08-21New trial registeredalbiglutideSafety and Efficacy Study of Albiglutide in Type 2 Diabetes
NCT00849017 · GlaxoSmithKline
Completed, n=309P3
2026-08-21New trial registeredalbiglutideEffect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
NCT02465515 · GlaxoSmithKline
Completed, n=9,463P4
2026-08-21New trial registeredalbiglutideA Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
NCT01777282 · GlaxoSmithKline
Completed, n=374P3
2026-08-21New trial registeredalbiglutideAlbiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
NCT01475734 · GlaxoSmithKline
Completed, n=44P2
2026-08-21New trial registeredalbiglutideSafety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00849056 · GlaxoSmithKline
Completed, n=310P3
2026-08-21New trial registeredalbiglutideIn-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus
NCT00354536 · GlaxoSmithKline
Completed, n=60P2
2026-08-21New trial registeredalbiglutideExtension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
NCT02750930 · GlaxoSmithKline
Terminated, n=8P4
2026-08-21New trial registeredalbiglutidePharmacokinetics/Pharmacodynamics of Albiglutide
NCT01357889 · GlaxoSmithKline
Completed, n=283P2
2026-08-21New trial registeredalbiglutideSafety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
NCT02683746 · GlaxoSmithKline
Completed, n=308P3
2026-08-21New trial registeredalbiglutideAlbiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
NCT02229240 · GlaxoSmithKline
WithdrawnP3
2026-08-21New trial registeredalbiglutideA Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
NCT02496221 · GlaxoSmithKline
Completed, n=20P4